Introduction
Lymphomas comprise the fifth most common cancer type in the United States, with approximately 55 000 cases of nonHodgkin's lymphoma (NHL) and 7400 cases of Hodgkin's lymphoma each year. An unexplained finding is the 80% rise in NHL in the last three decades. 1 Unfortunately, there has been little or no progress in improving survival for patients with aggressive and indolent lymphomas for several decades. 2 The emergence of clinical drug resistance continues to be an obstacle for the successful treatment of lymphoma. It is generally believed that many cancers develop resistance to drugs as a result of the selection of rare mutant cells which are resistant to the cytotoxic action of certain drugs. Most research on drug resistance so far has focused on identifying genetic, epigenetic and phenotypic properties of tumor cell based unicellular drug selection. The unicellular drug-resistant model has been critical in elucidating drug-resistance mechanism and in some cases has aided in the identification of drug targets. However, these models do not address resistance mechanisms that contribute to de novo drug resistance. The cancer cell is only part of the story in tumorgenesis. As a cancer cell grows within the elaborate architecture of the body's tissues and organs, it interacts with its surrounding environment. 3 Mounting evidence now suggests that a dynamic interaction occurs between the tumor (lymphoma) cell and its local (bone marrow) and systemic environment, with each profoundly influencing the behavior of the other. This 'tumor microenvironment' is a critical determinant for tumor initiation, progression, response to therapy and drug resistance. [4] [5] [6] We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumor cells that affords a survival advantage (due to stromal-tumor cell-cell interaction) following initial drug exposure, and may facilitate the acquisition of acquired drug resistance. However, how bone marrow microenvironment influences lymphoma cell survival and the cellular response to therapy, as well as the molecular mechanisms involved, is unclear to date.
The incidence of bone marrow involvement by NHL varies 40-80% in low-grade indolent lymphomas and 20-60% in intermediate-and high-grade lymphomas. 7, 8 The mere presence of residual lymphoma in the marrow is a predictive for a poor outcome. 9, 10 Undetectable subpopulations of tumor cells that survive drug treatment consequently lead to relapse. 11, 12 The interaction between bone marrow stromal cells (BMSCs) and lymphoma cells regulates tumor cell response to chemotherapy on at least two different levels: first, adhesion receptors and their cognate ligands expressed on the surface of both lymphoma and stromal cells function as signaling molecules capable of altering the proliferative and survival behavior of lymphoma cells, secondly soluble factors produced by the stromal cells or sequestered in the extracellular matrix (ECM) may cooperatively or independently influence lymphoma cell behavior. Early studies and recent work have established that stromal cells prevent spontaneous or induced apoptosis in acute myelogenous leukemia, 13 acute lymphoblastic leukemia, 10, 14 and chronic lymphocytic leukemia 15 cells. In more recent studies, the human BMSC line HS-5 improved acute myeloid leukemia (AML) cell survival in vitro and attenuated chemotherapyinduced cell killing. 16, 17 Previous studies has reported that adhesion of hematopoietic malignant cell lines including myeloma, chronic myeloid leukemia and AML via b1 intergrin confers resistance to a variety of cytotoxic drugs as well as FAS mediated cell death. 18, 19 These studies further suggested that protective signals within the stromal microenvironment maintain residual leukemic or myeloma cell longevity, leading to the recurrence of the disease. Similar to that observed in acute lymphoblastic leukemia (ALL), AML and myeloma, the ability of BMSCs to regulate drug response and apoptosis either directly or by soluble factors has only been recently appreciated in NHLs. The focus of this study is to identify the molecular signal pathways, more specifically NF-kB activation pathway utilized by bone marrow and lymphoma cell-cell interaction. A mechanistic understanding of the cell adhesion-mediated protective mechanism provides potential to develop more effective, targeted novel treatment strategies.
Materials and methods

Cell lines
The human lymphoma cell lines, SUDH-10, SUDH-4 (CD19 þ , CD20 þ , CD10À, CD5À, CD3À, CD44À, diffuse large B-cell lymphoma (DLBL)) were provided by Dr M Raffeld, National Cancer Institute). The BMSC line, HS-5, was obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were grown in suspension in RPMI 1640 (Cellgro, Fischer Scientific Pittsburgh, PA, USA), supplemented with 5% fetal bovine serum (Omega Scientific, Turzana, CA, USA), and 1% (v/v) penicillin (100 U/ml), streptomycin (100 U/ml) and 1% (v/v) L-glutamine (GIBCO-BRL, Grand Island, NY, USA). Cells were fed after four days by adding one-half volume of complete medium, and then at weekly intervals by complete replacement of the medium until development of a confluent monolayer.
Patient lymphoma samples
The patient lymphoma cells were obtained from diagnostic fresh biopsy-derived lymphoma tissues. This study was conducted in accordance with the protocol approved by the Institutional Review Board. Informed consent was obtained from all patients. After Ficoll-Hypaque purification, the CD19-positive cells were positively isolated by using CD19 microbeads with the autoMACS magnetic cell sorter according to the manufacturer's instructions (Miltenyi Biotec Inc., Auburn, CA, USA). For small lymphocytic lymphoma and mantle cell lymphoma, FicollHypaque purification were not performed since these lymphomas usually have more than 80% of tumor cells in purity.
Cell cultures, reagents and antibodies
Either lymphoma cell lines or patient lymphoma cells (1.5 Â 10 6 cells/ml) were adhered to pre-established monolayers of HS-5, or kept in suspension for 12-24 h. Then, lymphoma cells were carefully removed, with the monolayer of HS-5 kept intact. The purity of the lymphoma cell population was greater than 90% analyzed by flow cytometry (CD19 vs CD44), and was used for experiments as described previously. 20 For transwell experiments, lymphoma cells were separated from HS-5 by transwell inserts.
The following polyclonal antibodies were purchased: caspases-3, 
Apoptosis detection assay
Lymphoma cells were cultured on a complete confluent monolayer of HS-5. After the indicated period of time, lymphoma cells were carefully removed with the monolayer of HS-5 kept intact. The purity of the lymphoma cell population was greater than 90%. Lymphoma cells were washed and stained with Annexin V FITC in accordance with the manufacturer's procedure (BD PharMingen, San Diego, CA, USA). Ten thousand events were analysed by flow cytometry (Becton Dickinson, San Jose, CA, USA) and CellQuest software (BD Biosciences, Mountain View, CA, USA) with at least three independent experiments performed.
RNase protection assay
RNA was isolated from either SUDH-4 or SUDH-10 cells using RNeasy columns according to the manufacturer's instructions (Qiagen) following adherence to HS-5 stroma cell line for 12-24 h. RNase protection assays were conducted using the BD PharMingen Riboquant hAPO-2c, or hAPO-3d, multi-probe templates, and the Pharmingen RiboQuant cell cycle kit according to manufacturer's protocol (Pharmingen, San Diego, CA, USA). The multi-probe template was prepared by 32 P incorporation in an in vitro transcription reaction, and free nucleotide was removed on a G50 column. Purified probe (1 Â 10 6 c.p.m. specific activity) was combined with 20 mg of total RNA. The hybridization reaction was carried out overnight at 561C. Samples were treated with RNase for 45 min at 301C and then with proteinase K for 15 min at 371C. Hybridized probes were extracted with phenol/chloroform/isoamyl alcohol and precipitated using ethanol. Samples were separated on a 5% denaturing gel (7 mM urea) and protected fragments were quantified by phosphor imaging analysis using Image Quant software (Molecular Dynamics, Sunnyvale, CA, USA).
Western blot
At the indicated time, cells were collected, washed twice with ice-cold PBS, lysed in the ice-cold lysis buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 0.1% Tween 20, 2 mM EDTA, 2 mM EGTA, 1 mM NaF, 0.1 mM NaVO 4 , 5mg/ml leupeptin, 0.2 mM PMSF and 1 mM dithiothreitol (lysis buffer). Following 30 min of incubation on ice, the lysates were sonicated and centrifuged at 12 000 g for 15 min at 41C. The lysates were quantified using Biorad reagent (Biorad, Hercules, CA, USA). Fifty micrograms of whole cell lysate were separated by 4-12% NuPage gel (Invitrogen), transferred to polyvinylidenefluoride membrane and blocked with 5% milk in TBS/T. Protein levels were examined with polyclonal antibodies to caspase-8, 9, PARP, XIAP, c-IAP1, c-IAP2, p50/105, p52/100, RelA, RelB, RelC and NIK, B-cell activating factor of TNF family (BAFF) (Upstate, Lake Placid, NY), washed with TBS/T and incubated with HRP-conjugated anti-rabbit secondary antibody for 1 h. The blot was subsequently stripped (100 mM betamercaptoethanol, 2% SDS 62.5 mM Tris pH 6.7 for 30 min at 501C) and reprobed for b-actin (Sigma, St Louis, MO, USA), and visualized with Lumi-Light chemiluminescence (Roche, Indianapolis, IN, USA) or SuperSignal-Dura Light (Pierce, Rockford, IL, USA). Protein bands were quantified by the Image Quant software program (Molecular Dynamics, Sunnyvale, CA, USA).
nuclear extracts were incubated with [ 32 P]dATP-labeled probe containing a kB site (Promega). DNA binding reactions were performed at room temperature for 30 min in a 10 ml mixture consisting of 4% glycerol, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5mM dithiothreitol, 50 mM NaCl, and 0.5 mg of poly (dI-dC). DNAprotein complexes were separated by 4% nondenaturing PAGE. To identify NF-kB subunits, nuclear extracts were incubated with Rel-specific antibodies for 60 min on ice prior to 
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T r a n s w e l l EMSA analysis Samples were resolved in 4% polyacrylamide gels. Specific bands were visualized by overnight exposure to X-ray films (Fuji, Stamford, CT, USA) at À701C. Quantitation of band intensity was performed on a Storm phosphor imager by means of ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).
Statistical analysis
The significance of differences between experimental conditions was determined using the 2-tailed Student's t test.
Results
BMSCs protect B lymphoma cell lines from druginduced apoptosis and protect primary B lymphoma cells against spontaneous apoptosis in culture by a combination of cell-cell contact and soluble factors
Previous studies have demonstrated that adhesion of myeloma and leukemia cells to the ECM component fibronectin (FN), and recently to BMSCs, significantly increased cellular resistance to a variety of cytotoxic drugs including topoisomerase II inhibitors. [20] [21] [22] [23] [24] We extended this study model to non-Hodgkin's B-cell lymphomas. Figure 1 demonstrated that BMSCs (HS-5) influenced the response of non-Hodgkin's B lymphoma cells to the topoisomerase II inhibitor, mitoxantrone. Although mitoxantrone is used less frequently than doxorubicin as an antilymphoma drug, it has been extensively characterized as a classic topoisomerase II inhibitor. We found that adhesion of lymphoma cells to HS-5 protected B-cell lymphoma cell lines SUDH-4 and SUDH-10 against mitoxantrone-induced apoptosis (Figure 1a) . Similar results were obtained for SUDH-4 and SUDH-10 when exposed to another widely used anti-lymphoma drug, dexamethasone (data not shown). Furthermore, we demonstrate that adhesion-dependent inhibition of mitoxantroneinduced apoptosis correlated with decreased activation of caspases-8 and 9, and cleavage of caspase-3 and PARP (Figure 1b , representative of four independent experiments). A similar protective effect on mitoxantrone-induced apoptosis by HS-5 was also observed with other lymphoma cell lines Jeko and Mino (data not shown).
Evidence has accumulated suggesting that tumor microenvironment can influence how cancer cells respond to chemotherapy by at least 2 different mechanisms, a cell-cell contact mechanism and a soluble mechanism. The contact interactions between cells or cell and ECM can regulate apoptosis and cell survival. The soluble mechanism involves production and secretion of certain factors by stromal cells contained in the tumor microenvironment. These soluble factors are then able to bind cell surface receptors of tumors cells and influence tumor behavior. Soluble factors produced by lymphoma cells and adjacent stromal cells have been implicated in the pathogenesis and progression of lymphomas. To examine the contribution of soluble factors independent of physical cell contact, we used transwell inserts to allow lymphoma cells to be juxtaposed to HS-5 without cell-to-cell contact. In order to include the soluble factors produced via dynamic interaction between bone marrow stroma and lymphoma cells, we performed the experiments by incubating lymphoma cells in the transwell insert (upper chamber) with coculture of HS-5 and SUDH-4 (10) in the lower chamber. As shown in Figure 1a and b (HS-5 þ transwell, or T), conditioned medium from coculture of lymphoma cells (SUDH-10) and BMSCs (HS-5) attenuated mitoxantrone-induced cell death in SUDH-10. Similar results were obtained for SUDH-4 and primary lymphoma cells exposed to mitoxantrone, indicating that soluble factor(s) play a role in bone marrow stromamediated drug resistance. As demonstrated in Figure 1a and b and four separate experiments revealed that coculture of HS-5 with lymphoma cells (SUDH-4 and SUDH-10) produced better protection (90%714, n ¼ 4) from mitoxantrone-induced apoptosis than that produced by transwell experiments (soluble factor, 50%78, n ¼ 4). This protection corresponded to the cleavage of caspases-8, 9 and PARP. These results implicated that both cell-cell contact and soluble factor are needed to confer full protection against apoptosis. Direct cell-cell contact may be essential for the maximal protection of lymphoma cells against apoptosis.
We further performed experiments to validate bone marrow stroma-mediated drug resistance in primary non-Hodgkin's B-cell lymphomas. Freshly isolated cells of various lymphomas were cultured alone in suspension or cocultured with HS-5 for 12 h. Cell apoptosis was determined by flow cytometry using Annexin V. Figure 1c and Table 1 showed that HS-5 cells attenuated spontaneous apoptosis in all primary B lymphoma specimens when cocultured with lymphoma cells (42.9712 in suspension and 18.077, in culture with HS-5, n ¼ 9, Po0.01, paired t test). The results could implicate that cell adhesionmediated drug resistance (CAM-DR) is operative in primary lymphoma cells.
Bone marrow stroma induces 'alternative' NF-kB pathway activation via NIK
The molecular mechanism of stroma-lymphoma interaction, and the molecular signaling pathways of cell adhesion-mediated drug resistance remain poorly understood. Collective evidence has accumulated linking the NF-kB pathway to governing apoptosis. Previously, our group showed that CAM-DR is associated with activation of NF-kB (RelB/p50) in myeloma cells. 25 To investigate involvement of NF-kB in non-Hodgkin's lymphoma, we performed experiments to measure NF-kB activation following lymphoma cell adhesion to HS-5. Figure 2a represents one of three separate experiments that showed lymphoma cell adhesion to HS-5 cells activates NF-kB Bone marrow stromal induced drug resistance T Lwin et al which resulted in the generation of active p52 and p52 accumulation in the nuclear extracts of SUDH4 and SUDH10 cells (Figure 2b) , which confirmed the translocation of p52 into the nucleus. Furthermore, cell adhesion induced proteolysis of p100 NF-kB2 occurred within 2 h upon cell adhesion as shown in Figure 2c . Since the processing of p100 is tightly regulated via a novel pathway mediated by NIK and the downstream I-kB kinase, 26, 27 we investigated the roles of NIK in the activation of the alternative pathway by cell adhesion. We next studied whether NIK is upregulated by BMSCs. Indeed as shown in Figure 2d , SUDH-4 and SUDH-10 adhesion to HS-5 increased the level of NIK. This finding further supports the notion of p100 processing to p52 pathway by stroma-lymphoma interaction and points to the existence of a novel (noncanonical) 'alternative' NF-kB signaling pathway that may thereby play a role in cell adhesion mediated protection against apoptotic death.
Bone marrow stroma induces expression of anti-apoptotic proteins, cIAPs and xIAP
Recent studies have implicated NF-kB-mediated gene expression in mechanisms of resistance to apoptosis induced by both physiological and cytotoxic stimuli. [28] [29] [30] Both cytotoxic drugs and death receptors initiate the proteolytic caspase cascade that cleaves essential cell proteins. Caspase activity is regulated at multiple points by proteins that are transcriptional products of NF-kB including Bfl-1A1, [31] [32] [33] Flice inhibitory protein, 34 Bcl-x L , 35 and the inhibitor of apoptosis (IAP) family. 36, 37 We therefore examined the protein expression of c-IAP1 and IAP2 and XIAP in lymphoma cells adhered to HS-5 vs in suspension. As shown in Figure 3a , c-IAP1, c-IAP2 and x-IAP proteins were significantly increased in cells adhered to HS-5 suggesting that these anti-apoptotic proteins may mediate the survival signals by which lymphoma cells maintain longevity, and are protected from cytotoxic apoptosis. Since a number of BCL-2 family members are also regulated by NF-kB, we next examined whether cell adhesion upregulated these molecules as well. As shown in Figure 3b , the levels Bcl-2 and Bcl-xL proteins were unchanged with and without BMSC adhesion indicating that protection by HS-5 was not via these BCL-2 family members.
Inhibition of NF-kB activation sensitizes lymphoma cells to drug-induced apoptosis
We next examined whether inhibition of NF-kB activation sensitizes lymphoma cells to drug-induced apoptosis. The following experiments were performed to assess whether neutralization of NF-kB by SN-50 (100 mM), a cell-permeable peptide that blocks nuclear translocation of NF-kB complexes, enhances lymphoma cell response to chemotherapy. Figure 4a shows that addition of SN-50 sensitized SUDH-10 cells to mitoxantrone in the presence of BMSCs, as well as overcame CAM-DR by HS-5 (representative of three independent experiments). Similar results were observed when NF-kB activity was inhibited by PS341 (50 nM), which overcame CAM-DR (Figure 4b ), again suggesting that HS-5 utilizes the NF-kB pathway to promote lymphoma cell survival (representative of three independent experiments). In addition, both SN-50 and PS341 inhibited NF-kB activity measured by ELASA (not shown) and induced SUDH-10 apoptosis in the absence of HS-5 demonstrating a basal constitutive activity of NF-kB in these lymphoma cells.
Inhibition of NF-kB activation overcomes CAM-DR through down regulation of anti-apoptotic proteins, c-IAPs and x-IAP in primary lymphoma cells
Given the ability of inhibition of NF-kB to enhance apoptosis and overcome CAM-DR, the combination of NF-kB inhibitors and cytotoxic drug may be a more optimal treatment for B-cell malignancies. We next further validated such an approach in primary lymphomas in vivo. We determined whether CAM-DR observed in lymphoma cell lines were operative in primary lymphoma cells. We examined if the inhibition of NF-kB activation overcomes CAM-DR in primary cells. Finally, we investigated the molecular mechanism and determined if inhibition of NF-kB activation suppresses the cell adhesion induced upregulation of anti-apoptotic proteins such as c-IAP and x-IAP. Figure 5a was a representative sample of primary lymphoma cells (follicular lymphoma) showing inhibition of NF-kB by PS341 indeed enhanced mitoxantrone-induced cell apoptosis in the presence of stroma (cell adhesion and transwell). Figure 5b demonstrated that inhibition of NF-kB activation overcomes CAM-DR through down regulation of antiapoptotic proteins, c-IAPs and x-IAP in primary lymphoma cells. Table 2 was a summary of such experiments on five primary lymphoma samples. As shown in this table, similar to the cultured lymphoma cell lines, cell adhesion and soluble factor (transwell) both protected primary lymphoma cells from spontaneous and drug-induced apoptosis. PS341 overcame cell-adhesion mediated drug resistance and enhanced drug induced apoptosis in these primary lymphoma cells. Overall, this study implicated bone marrow stromal control of lymphoma cell survival via NF-kB dependent pathway. 
Discussion
NHL cells are often localized in bone marrow where they come into direct contact with bone marrow stroma. Previous studies have demonstrated that bone marrow stroma contributes greatly to the development of drug resistance to chemotherapy in multiple myeloma (MM), acute and chronic myelogenous leukemia cells and B-lineage acute lymphoblastic leukemia. 16, 17, 20, 24, 38 However, the precise mechanism of this effect was unclear. In this study, we investigated the effects of stromal cells on NHL cell survival in cell lines and in primary NHL samples. We demonstrate a critical role of NF-kB activation in the cell adhesion mediated protection of lymphoma from druginduced apoptosis. We characterize an NF-kB activation signaling pathway by which cell adhesion regulates lymphoma cell survival and mediates drug resistance. For the first time, we show 'alternative' NF-kB pathway activation and subsequent processing of NF-kB2 (p100) to p52 by cell-cell interaction.
Accumulating evidence has suggested that survival signals can be provided by interactions between chronic lymphocytic leukemia (B-CLL) cells and their bone marrow microenvironment. 39 It has been demonstrated that survival of B-CLL cells can be induced by BMSCs, through an integrin-dependent mechanism. 40 Contact with BMSCs has also been reported to induce proliferation and sustain survival of ALL cells in culture. 41, 42 CLL B-cell survival in vitro can also be promoted through direct contact with immobilized substrata produced from FN, correlating with an increase in the ratio of Bcl-2 to Bax. 43 In addition, it has recently been shown that FN and BMSCs inhibited drug-induced apoptosis in MM cells. 21, 24 Thus, multiple environmental signals may modulate the survival and clonal expansion of neoplastic B cells in vivo. Here, we extend First, we tested the ability of HS-5 cells to prevent apoptosis in the lymphoma lines SUDH-4 and SUDH-10 and in primary lymphoma samples. When suspended, SUDH-4 and SUDH-10 cells rapidly underwent apoptosis following addition of mitoxantrone, as evidenced with Annexin V in flow cytometric assays. However, cell death was significantly delayed and reduced when SUDH-4 and SUDH-10 grown in coculture with HS-5 cells. HS-5 cells also reduced spontaneous apoptosis in all nine primary lymphoma samples tested. This observation confirmed results of previous studies that demonstrated the ability of stromal cells to regulate the survival of leukemic cells. 13, 15 We then examined the effects of direct stromal contact and of conditioned medium derived from coculture of HS-5 and lymphoma cells on the survival of lymphoma cells. Stroma/ lymphoma coculture-conditioned medium was able to maintain the survival of SUDH 4 and SUDH10 lymphoma cells when exposed to mitoxantrone. However, grown in direct contact with stromal cells, lymphoma cells were better protected than in stroma/lymphoma coculture-conditioned medium from drug induced apoptosis. These results suggest a role for soluble factors, as well as cell-to-cell contact, in the survival of lymphoma cells. When lymphoma cells were separated from HS-5 by microporous insert (transwell), an anti-apoptotic effect was observed but to a lesser degree compared with direct stroma-lymphoma contact in this study. These data suggest that direct cell-to-cell contact is necessary for maximal antiapoptotic effects in this used model. Similar results have been reported in acute myelogenous leukemia. 17 The ability of HS-5 stromal cells to synthesize cytokines such as BAFF, lymphotoxin-b and CD40 ligand that may bind distinct receptors could constitute an additional mechanism by which the stroma supports these cells.
To explore the mechanism underlying the enhanced survival afforded by coculture with stromal cells, we examined both the classical and alternative activation pathways of NF-kB following lymphoma cell adhesion to HS-5. In this study we demonstrated that cell adhesion to HS-5 activates NF-kB in B lymphoma cells not only through the classical pathway but also through the alternative pathway. Upon cell adhesion to HS-5 the p100 NFkB2 precursor protein is processed into p52, which dimerizes with p65 (RelA) and RelB and translocates to the nucleus to regulate kB-dependent gene transcription. We show that cell adhesion induces processing of the p100/NF-kB2 precursor into p52, which translocates into the nucleus. In addition, we for the first time, demonstrates that cell adhesion activates NIK, the NF-kB-inducing kinase, the well-known upstream effector of alternative NF-kB signaling pathway, leading to the ubiquitination and proteasomal processing of p100 into p52. 27 We therefore anticipate the involvement of NIK protein in the activation of the NF-kB pathway by stroma-lymphoma interaction.
The results reported here demonstrate that bone marrow stroma, through cell adhesion, activates alternative (noncanonical) NF-kB signaling pathways to promote cell survival. The use of a different NF-kB pathway results in the activation of a different combination of Rel dimers. For example, in Daudi cells IFN induces the canonical NF-kB pathway resulting in the activation of c-Rel-p50 heterodimers, whereas the noncanonical pathway results in RelA-p52 dimers. TNF activates the canonical NF-kB pathway, and adhesion of MM activates NF-kB through p50-RelB dimers. 25 Therefore, the differential activation of canonical and noncanonical NF-kB pathways is highly dependent on the type of stromal cells and the cell lineage. In our model we anticipate that bone marrow stroma-derived molecules such as BAFF, lymphotixin-b and CD40L play a critical role in NF-kB activation. It is well known that BAFF, lymphotixin-b and CD40L sustain B-cell survival through noncanonical NF-kB activation pathways. Additional experiments would be needed to elucidate the role of specific stromal cell-derived cytokines in the regulation of stroma-mediated lymphoma cell survival.
We searched for the expression of cIAP and Bcl-2 family member proteins that were capable of influencing the resistance or sensitivity of lymphoma cells to apoptosis, since expression of both families are regulated by NF-kB. The Bcl-2 family consists of homologous proteins that control apoptosis at the level of mitochondria. 44 Bcl-2 family members with homology only in the BH3 (Bcl-2 homology 3) domain, such as Bid, are sensors for cellular stress signals. BH3-domain only Bcl-2-like proteins promote the activation of other pro-apoptotic Bcl-2 homologous proteins, such as Bax and Bak. These proteins stimulate the release of cytochrome c and second mitochondria-derived activator of caspases (SMAC) from the mitochondria. 45 Antiapoptotic Bcl-2 family proteins, like Bcl-2 and Bcl-xL, inhibit the release of these factors. In the cytosol, cytochrome c can induce the activation of caspases and subsequent apoptotic degradation of the cell. SMAC promotes caspase-activation by blocking members of the IAP family. 46, 47 The IAP family is a relatively new group of apoptosis-regulating proteins, which consists of a number of proteins that can bind to and inhibit caspases. 48 Furthermore, there is growing evidence that members of the IAP family, including c-IAP1, c-IAP2, XIAP and survivin, are involved in a variety of cancers. 49 In this study, analysis of mRNA expression and protein did not demonstrate any significant difference in Bcl-2 family member expression following adhesion of lymphoma cells to Table 2 PS341 overcomes cell adhesion mediated drug resistance (CAM-DR) in primary lymphoma cells 1  DLCL  10  45  52  61  5  41  32  65  9  41  40  59  2  FCL  12  47  45  65  6  33  39  70  11  45  41  68  3  SLL  35  ND  68  ND  19  ND  29  ND  35  ND  65  ND  4  MCL  25  ND  62  ND  17  ND  39  ND  23  ND  53  ND  5  MCL  30  ND  58  ND  23  ND  46  ND  39  ND  42  ND Abbreviations: DLBL, diffuse large B-cell lymphoma; Dx, diagnosis; FCL, follicular lymphoma; MCL, mantle cell lymphoma; ND, not done; P, PS341; PT, patients; SLL, small lymphocytic lymphoma. Primary lymphoma cells from 5 patients were maintained in suspension (Sus) or adhered to the pre-established monolayer of HS-5 (HS5-Ad), or in transwell insert (Transwell) were treated with and without (C) mitoxantrone (M, 2 mM) alone or PS341 (PS, 50 nM) alone or mitoxantrone plus PS341 (PS+M) for 2 hours and measured by flow cytometry using Annexin V.
HS-5, although high levels of constitutive bcl-2 and bcl-xl proteins were identified. This result is in agreement with previous studies in MM. 25 Additional study revealed that direct cell-cell contact rather than stroma-derived soluble factor induced upregulation of c-IAP family members, c-IAP1, c-IAP-2 and x-IAP. This is based on the finding that conditioned medium from stroma/lymphoma coculture has no effect on c-IAP family members. A similar observation was seen in MM demonstrating induction c-IAP1, c-IAP-2 and x-IAP by cell adhesion onto FN in MM cells and further supported the role of direct cell-cell contact in cell adhesion mediated cell survival. Our experiments demonstrated that PS341suppressed cell adhesion mediated upregulation of anti-apoptotic proteins, c-IAP and x-IAP, which likely contributed to its effect in overcoming CAM-DR. Inhibition of NF-kB sensitized drug-induced apoptosis in both cell adhesion and transwell experiments of primary samples, implicating that NF-kB activation pathway is involved in both cell-cell contact and soluble factor mediated drug resistance. Given pro-survival effect of BAFF on B-lymphocytes via NF-kB activation, it would be interesting to study the role of BAFF in the interaction between stroma and lymphoma cells.
In recent years, many studies have revealed links between members of the IAP family and the development of hematological cancer. [48] [49] [50] Both c-IAP1 and c-IAP2 can promote survival through multiple mechanisms, including caspase inhibition, proteosomal degradation and nuclear factor-kB activation. 48 High levels of cIAP-2 and c-IAP1 could therefore enhance apoptosis resistance, which may contribute to the development of lymphoid malignancies. High expression of IAP family members c-IAP1, c-IAP2 (and x-IAP) has been reported before in CLL and was suggested to be part of an anti-apoptotic profile mediated by tumor necrosis factor receptor-associated factor 1 (TRAF1) and, to a lesser extent, tumor necrosis factor receptorassociated factor 2 (TRAF2). 51 Our data implicate that the expression of three genes belonging to the IAP family, c-IAP1, c-IAP2 and X-IAP, were upregulated by direct stroma-lymphoma cell-cell contact. We hypothesize that the induction of c-IAP family expression by cell adhesion could be responsible, and that it contributes to resistance to both physiological-and cytotoxic-induced apoptosis in lymphomas. It would also be interesting to investigate whether IAP expression correlates with clinical outcome or therapeutic efficacy in lymphomas, and whether it may be a good target for new therapeutic strategies. Finally, we demonstrated that inhibition of NF-kB activation by SN50 and PS341 could overcome stroma-mediated drug resistance in both lymphoma cell lines and primary lymphoma cells, confirming the role of the NF-kB signaling pathway in survival of lymphoma cells in the bone marrow microenvironment. Given the ability of inhibition of NF-kB to enhance apoptosis and overcome CAM-DR, the combination of NF-kB inhibitors and cytotoxic drug may be a more optimal treatment for B-cell malignancies. This study therefore provides the rational to target NF-kB signaling pathway in novel therapeutics.
